Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa Study of OsteoDex (ODX) in Multiple Myeloma
2024-516969-36-00Phase 2Completed
- Sponsor
- DexTech Medical
- Start
- Sep 2024
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OsteoDex in multiple myeloma (MM), sponsored by DexTech Medical. Primary endpoint: Safety and tolerability of OsteoDex. Started Sep 2024; status: completed.
02
Drugs
OsteoDex
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-516969-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516969-36-00.